Other Clinical Trial - Omega 3 Plus Vaginal Progesterone on Birth Weight

Status Completed

Clinical Trial Summary

Small for gestational age refers to an infant born with a birth weight less than the 10th centile. Severe small for gestational age refers to an infant born with a birth weight less than the 3rd centile. Constitutionally small fetuses are fetuses whose growth at all gestational ages has been low but otherwise healthy. Those babies have a great risk for perinatal morbidity and mortality. Many causes are responsible for the development of Severe small for gestational age, however; in a few cases, the cause could not be detected. In contrast to pathologic intrauterine growth restriction, the constitutionally small fetuses have normal umbilical and middle cerebral artery Doppler velocimetry and normal amniotic fluid volume. In this circumstance, continued biophysical testing and delivery at 38-39 weeks is reasonable. Low birth weight fetuses comprise both preterm births and SGA. They are at a higher risk of adverse birth outcomes. So the trials to increase the blood flow to the uterus and/or the fetus may improve the neonatal outcomes. There are many lines of treatment that have been emerged now for the treatment of small for gestational age fetuses like maternal rest and oxygenation, aspirin therapy, supplementation of zinc, and fish oil. However; all mentioned lines of treatment lack evidence of effectiveness in literature. Omega-3 fatty acids as antioxidants inhibit the free radicals released during pregnancy which are responsible for vasoconstriction; so vasodilatation will occur. This leads to increase blood flow to the uterus and placenta which improves pregnancy outcomes. Progesterone is a smooth muscle relaxant and has a vasodilator effect on the blood vessels. It causes endothelium- relaxation of human placental arteries and veins. This relaxation is significant for maintaining low flow impedance and satisfactory blood flow in the placental circulation. DeFranco et al observed that vaginal progesterone is associated with vascular relaxation and increased uterine blood flow. But, he did not observe this vascular effect in women receiving systemic progesterone. So from the above evidence; there is a need to study the effect of omega 3 and progesterone on pregnant women whose pregnancy is complicated with constitutionally small for gestational age fetuses in trial to find a new line of treatment of this problem.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Birth Weight
Small for Gestational Age at Delivery

Clinical Trial Details

NCT number	NCT04161989
Study type	Interventional
Source	Assiut University
Contact
Status	Completed
Phase	N/A
Start date	May 1, 2020
Completion date	June 1, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03215173` - Fit After Baby: Increasing Postpartum Weight Loss in Women at Increased Risk for Cardiometabolic Disease	N/A
Completed	`NCT03533712` - Effect of a Fortified Balanced Energy-Protein Supplement on Birth Outcome and Child Growth in Houndé District, Burkina Faso.	Phase 4
Recruiting	`NCT05901688` - Umbilical Cord Abnormalities in the Prediction of Adverse Pregnancy Outcomes
Recruiting	`NCT06315127` - The CanDo (Canadian Donor Milk) Trial	N/A
Completed	`NCT04216706` - Early Vascular Adjustments to Prevent Preeclampsia
Recruiting	`NCT05855551` - Improving Birth Outcomes in Bangladesh	N/A
Not yet recruiting	`NCT06226051` - Growing Little PEAPODS Study
Completed	`NCT01728766` - Breast Milk Zinc Transfer to Appropriate- and Small-for-gestational-age Bangladeshi Infants	N/A
Not yet recruiting	`NCT06200519` - Assessment of Diastolic Function During the Transitional Period and Infancy Using Serial Echocardiography
Not yet recruiting	`NCT05670145` - PRECISE - Objective Measures and Observations of Physical Exposures Among Pregnant Employees in the Danish Workforce
Completed	`NCT05810545` - Drinking Water PFAS, Pregnancy Outcome and Maternal Morbidity
Completed	`NCT05814198` - Evaluation of HALP Score in Distinction Between FGR and SGA
Recruiting	`NCT04764461` - Use of Customized GROW Charts for Detection of SGA in Low Risk Woman.	N/A
Recruiting	`NCT04720690` - Bioimpedence and Arterial Function Monitoring at Birth and in Infants
Recruiting	`NCT06125860` - BEP Targeting Strategies in Ethiopia	N/A
Active, not recruiting	`NCT06074601` - MIRACLE of LIFE Study
Completed	`NCT03880032` - Happy Mother-Healthy Baby: An Anxiety-focused Early Prenatal Intervention	N/A
Withdrawn	`NCT05612984` - Calcium Aspirin Multiple Micronutrients (CAMMS) to Reduce Preterm Birth	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Omega 3 Plus Vaginal Progesterone on Birth Weight of Constitutionally Small for Gestational Age Fetuses

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms